The data obtained reveal that among the 445 samples collected at diagnosis, those from patients who developed a prior MDS or a prior MPN exhibit a higher level of AKT3 expression (although not significant for the “prior MPN” category likely due to an insufficient number of samples), but not of AKT1 or AKT2 (Fig. 6, right). This evidence concerns the gene AKT2 and myeloproliferative neoplasm.